It is known
that the goal of vaccine developers is to mimic a natural infection as closely
as possible without getting a healthy individual sick.
The arrival
of Covid-19 vaccines promises a return to more normal life and has created a
global market worth tens of billions of dollars in annual sales for some
pharmaceutical companies.
Pfizer
- One of the
world’s largest pharmaceutical companies, based in New York, in collaboration
with German biotech company BioNTech.
- According
to the first-quarter results published by Pfizer this week, its coronavirus jab
BNT162b2, made in partnership with BioNTech, has reaped revenues of $3.5bn for
the biopharma giant in the first three months of 2021.
- Governments
have ordered about 780m shots, including the US (200m doses for $3.9bn) and the
EU commission (300m), while 40m doses will go to lower-income nations via the
Covax facility. It costs $39 (£28) for two doses in the US and about $30 in the
EU.
- Expected sales in 2021: $15bn-$30bn
Moderna
- A
Massachusetts-based biotech company, in collaboration with the National
Institutes of Health.
- The vaccine
brought Moderna revenue of $1.73 billion in the first quarter, reflecting three
full months of its use in the U.S. and initial international sales, the company
said Thursday.
- The UK has
ordered 17m doses, the EU bought 310m with an option for a further 150m in
2022, while the US government ordered 300m shots. Japan purchased 50m shots.
Moderna charges $30 for the required two shots in the US and $36 in the EU.
- Expected sales in 2021: $18bn-$20bn
Johnson &
Johnson
- One of the
world’s largest multinational corporations, based in New Jersey, specializing
in healthcare and pharmaceutical products.
- It was
approved in the US in late February and can be stored at standard fridge
temperatures for at least three months. Big orders include the US, UK (30m
doses plus option for 22m), the EU (up to 400m doses), and Covax nations (500m
doses through 2022).
- Expected
sales in 2021: up to $10bn
Read more: Comparing vaccines: country of origin, safety, price, efficacy, and approval
AstraZeneca
- The U.K.
university, in collaboration with the biopharmaceutical company AstraZeneca.
- AstraZeneca’s
Covid vaccine brought in $275 million in 2021 first-quarter revenue
- In an
upbeat earnings report today , Anglo-Swedish drugmaker AstraZeneca reported
$275 million in revenue from its Covid-19 vaccine in the first three months of
the year.
- Big orders
have come from the UK (100m), the EU (up to 400m), the US (300m) and Japan
(£120m).
- Expected
sales in 2021: $2bn-$3bn
Read All Articles Here
